REP 2139-Ca

DRUG2 trials

Sponsors

Replicor Inc.

Conditions

Hepatitis B, Chronic

Phase 1

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

CompletedNCT02646189

Replicor Inc.Hepatitis B, Chronic

Start: 2011-08-31End: 2013-08-31Updated: 2016-01-05

Phase 2

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

CompletedNCT02726789

Replicor Inc.Hepatitis B, Chronic

Start: 2012-10-31End: 2016-12-31Updated: 2019-05-08

Related Papers

Kinetics of hepatitis B surface antigen quasispecies during REP 2139‐Ca therapy in HBeAg‐positive chronic HBV infection

Journal of Viral Hepatitis2019-07-199 citations

Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol

Zeitschrift für Gastroenterologie2019-01-01

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

PLoS ONE2016-06-03176 citations